Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.56 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.49 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.48 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3732747 | 0.88 | OPRL1 (0.74) | OPRL1ALDH1A1 | |
| SCHEMBL3730104 | 0.84 | OPRL1 (0.58) | OPRL1ALDH1A1EGLN1C5AR1PTGDR2 | |
| SCHEMBL3733515 | 0.81 | OPRL1 (0.54) | OPRL1ALDH1A1EGLN1LMNAC5AR1 | |
| SCHEMBL2256110 | 0.76 | EGLN1 (0.53) | OPRL1EGLN1PTGDR2 | |
| SCHEMBL2254486 | 0.75 | EGLN1 (0.52) | OPRL1EGLN1PTGDR2 | |
| SCHEMBL2254620 | 0.75 | EGLN1 (0.52) | OPRL1ALDH1A1EGLN1 | |
| SCHEMBL2255992 | 0.74 | EGLN1 (0.58) | OPRL1EGLN1C5AR1 | |
| SCHEMBL3739268 | 0.74 | PTGDR2 (0.47) | OPRL1ALDH1A1EGLN1LMNAC5AR1 | |
| SCHEMBL18729423 | 0.73 | OPRL1 (0.61) | OPRL1ALDH1A1EGLN1C5AR1 | |
| SCHEMBL9774497 | 0.72 | PTGDR2 (0.48) | OPRL1ALDH1A1EGLN1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2009061676-A2 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009061676-A2 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | PTGDR2, PTGDR, LTB4R2 | OPRL1 233/4885IP6K1 1556/4885ALDH1A1 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.